UBS AM’s 4D Molecular Therapeutics FDMT Stock Holding History

UBS AM’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.19K	Hold	691	–	–	﹤0.01%	3299
2026 Q1	$6.43K	Buy	+691	New	+$6.01K	﹤0.01%	3404
2025 Q1	–	Sell	-44,324	Closed	-$247K	–	2662
2024 Q4	$247K	Buy	44,324 +2,925	+7%	+$23K	﹤0.01%	2625
2024 Q3	$448K	Sell	41,399 -6,253	-13%	-$104K	﹤0.01%	2668
2024 Q2	$1M	Buy	47,652 +15,574	+49%	+$391K	﹤0.01%	2369
2024 Q1	$1.02M	Buy	32,078 +8,490	+36%	+$217K	﹤0.01%	2003
2023 Q4	$478K	Hold	23,588	–	–	﹤0.01%	2332
2023 Q3	$300K	Buy	23,588 +13,439	+132%	+$225K	﹤0.01%	2435
2023 Q2	$174K	Hold	10,149	–	–	﹤0.01%	2586
2023 Q1	$174K	Buy	+10,149	New	+$197K	﹤0.01%	2586
2022 Q4	–	Sell	-26,894	Closed	-$216K	–	2619
2022 Q3	$216K	Buy	26,894 +13,712	+104%	+$124K	﹤0.01%	2584
2022 Q2	$92K	Hold	13,182	–	–	﹤0.01%	2654
2022 Q1	$199K	Hold	13,182	–	–	﹤0.01%	2682
2021 Q4	$289K	Buy	+13,182	New	+$323K	﹤0.01%	2684

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

UBS AM's FDMT Position: Q2 2026 in Review

UBS AM held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 691 shares worth $9.19K. The position accounts for ﹤0.01% of the portfolio, ranked #3299.

UBS AM first reported a position in FDMT in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.02M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

UBS AM held 691 shares of 4D Molecular Therapeutics worth $9.19K as of Q2 2026.
UBS AM left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
4D Molecular Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3299 holding.
UBS AM first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 14 quarters since.
UBS AM's 4D Molecular Therapeutics position peaked at $1.02M in Q1 2024.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.